Golden Child | $37,000,000 | (Apr 29, 2026)
Windmill(US) | $12,000,000 | (Apr 29, 2026)
Lighthouse Pharmaceuticals
United States
- San Francisco Bay Area
- 29/04/2026
- Series A
- $12,000,000
Lighthouse develops small-molecule therapeutics, leveraging translational insights and extensive clinical experience to address chronic degenerative and inflammatory disorders, with a lead clinical program focused on Alzheimer’s disease. The SPRING Clinical Trial is now recruiting across the US. www.springclinicaltrial.com
- Industry Biotechnology Research
- Website https://www.lighthousepharma.com/
- LinkedIn https://www.linkedin.com/company/lighthouse-pharmaceuticals/
Related People
Casey LynchFounder
United States -
San Francisco, California
Director, entrepreneur and investor with proven background in company building including as a public company CEO. Focused on advancement of innovative science including drug and device development, efficient value growth, capital raising, due diligence, and acceleration of translational research into and through the clinic. Angel investor and current LP in a variety of venture funds including biotech, creative bioscience, tech, blockchain, women-led and secondary equity as well as several hospitality endeavors.
Liquid Instruments | $50,000,000 | (Apr 29, 2026)
TriFetch | $1,900,000 | (Apr 28, 2026)
Fathom Therapeutics | $47,000,000 | (Apr 28, 2026)
SquareMind | $18,000,000 | (Apr 28, 2026)
Linexa | $2,342,840 | (Apr 28, 2026)
Iridius | $8,600,000 | (Apr 28, 2026)
Decade Energy | $25,763,540 | (Apr 28, 2026)
HrFlow.ai | $7,000,000 | (Apr 28, 2026)
Cnuic Technologies | $3,000,000 | (Apr 28, 2026)